NCT06993766View on ClinicalTrials.gov

The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

May 1, 2030

Study Completion Date

May 31, 2030

Conditions

Relapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy

All Listed Sponsors

lead

King Faisal Specialist Hospital & Research Center

OTHER